Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 16/20 | 0.65 |
| ▸ | MAOB | P27338 | 4/20 | 0.58 |
| ▸ | MAOA | P21397 | 3/20 | 0.58 |
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3297540 | 0.99 | ACHE (0.67) | ACHEMAOBMAOABCHE | |
| SCHEMBL3298737 | 0.91 | ACHE (0.78) | ACHEMAOBMAOABCHE | |
| SCHEMBL3300157 | 0.91 | ACHE (0.78) | ACHEMAOBMAOABCHE | |
| Hydrochloric Acid SCHEMBL3298733 | 0.90 | ACHE (0.80) | ACHEMAOBMAOABCHE | |
| SCHEMBL3298376 | 0.89 | ACHE (0.82) | ACHEMAOBMAOABCHE | |
| SCHEMBL5319127 | 0.89 | ACHE (0.69) | ACHEMAOBMAOABCHEHRH3 | |
| Hydrochloric Acid SCHEMBL3299642 | 0.88 | ACHE (0.84) | ACHEMAOBMAOABCHE | |
| SCHEMBL12043623 | 0.85 | ACHE (0.82) | ACHEMAOBMAOABCHE | |
| Fumaric Acid SCHEMBL3301189 | 0.83 | ACHE (0.62) | ACHEMAOBMAOABCHEHRH3 | |
| SCHEMBL12043634 | 0.83 | ACHE (0.71) | ACHEMAOBMAOABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007100583-A2 | PROPARGYLATED AMINOINDANS, PROCESSES FOR PREPARATION, AND USES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-09-07 | — | — | WO | claimed |
| US-20070203232-A1 | Propargylated aminoindans, processes for preparation, and uses thereof | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2007-08-30 | — | — | US | claimed |
| US-8609719-B2 | Propargylated aminoindans, processes for preparation, and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2013-12-17 | — | — | US | disclosed |
| US-20100093848-A1 | PROPARGYLATED AMINOINDANS, PROCESSES FOR PREPARATION, AND USES THEREOF | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2010-04-15 | — | — | US | disclosed |
| US-7625946-B2 | Propargylated aminoindans, processes for preparation, and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2009-12-01 | — | — | US | disclosed |
| WO-2007100583-A2 | PROPARGYLATED AMINOINDANS, PROCESSES FOR PREPARATION, AND USES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-09-07 | — | — | WO | disclosed |
| US-20070203232-A1 | Propargylated aminoindans, processes for preparation, and uses thereof | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203232-A1 | Propargylated aminoindans, processes for preparation, and uses thereof | PRMT3, PRMT1, PNMT | ACHE 76/4885MAOB 510/4885MAOA 511/4885 |
| US-20100093848-A1 | PROPARGYLATED AMINOINDANS, PROCESSES FOR PREPARATION, AND USES THEREOF | DNPEP, PEPD, ACHE | ACHE 3/4885MAOB 1332/4885MAOA 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.